EPICOR
9.3.2022 16:02:10 CET | Business Wire | Press release
Epicor, a global provider of industry-specific enterprise software to promote business growth, today announced its Partner Excellence Award winners at the Momentum Partner Conference 2022.
Now in its sixth year, the event recognises industry Partners that have outperformed in their commitment to the growth of Epicor business, through innovation and cloud technology with their customers.
“A record number of nominations were received this year and our Partners exceeded all expectations as they continued to demonstrate strong expertise and innovation in helping our customers,” said Paul Flannery, VP of International Channel Sales at Epicor.
At the virtual ceremony, Partners were recognized for their achievements across five categories showcasing excellence in industry expertise, business transformation, cloud transformation, and overall business success. Winners included:
Industry Specialist Award – Finsoft Consulting Sdn Bhd was named Industry Specialist winner for delivering a Best-in-Class solution for its customer – a leading supplier in the rubber glove industry, challenged in coping with rising market demand. The team customised a suite of Epicor solutions that solved challenges other ERP systems could not address. The integration enabled the customer to quadruple market share in a highly critical market.
Business Transformation Award – Grand Target Information Technology Ltd secured a win in the Business Transformation category after taking its customer on a comprehensive Industry 4.0 journey, engaging them in a change management experience throughout. The team improved its customer’s business workflow by opening data chains across ERP, PLM, MES and WMS systems, integrating module solutions, and migrating the customer toward a fully integrated digital twin smart factory.
Cloud Transformation Award – Panamax Infotech Ltd was awarded Cloud Transformation winner for delivering an impressive 80 percent of its business on new cloud accounts, winning deals during a time of challenging market conditions, and increasing deal sizes. Panamax also secured the first Epicor cloud customer in India, going live in less than six months.
Rising Star Award – This year’s rising star award went to Clear Business Outcome Ltd, chosen for significant growth through a regional focus and expertise in both sector and technology platform, its unique ‘Engine for Growth’ demand generation programmes, and its transformation from Consultancy to an end-to-end sales-led operational business model.
International Partner of the Year Award – Consistent performance over many years earned Aspera Solutions the coveted International Partner of the Year award, delivering strong and consistent year-over-year growth executed in each of Epicor’s strategic areas – cloud, key new accounts, migrations, add-on sales and platform sales on both Kinetic and Prophet 21 platforms.
“Congratulations to Aspera and all our winners! Partner recognition is very important to Epicor as we celebrate these achievements and international success. We thank you all for your hard work and commitment and look forward to accelerating our success over the next 12 months,” commented Andy Coussins, Senior Vice President and Head of International at Epicor.
For more information on the Epicor Partner Network please visit our website .
About Epicor
Epicor equips hard-working businesses with enterprise solutions that keep the world turning. For 50 years, Epicor customers in the automotive, building supply, distribution, manufacturing, and retail industries have trusted Epicor to help them do business better. Innovative Epicor solution sets are carefully curated to fit customer needs and built to respond flexibly to their fast-changing reality. With deep industry knowledge and experience, Epicor accelerates every customer’s ambition, whether to grow and transform, or simply become more productive and effective. Visit www.epicor.com for more information.
Epicor and the Epicor logo are trademarks of Epicor Software Corporation, registered in the United States and other countries. Other trademarks referenced are the property of their respective owners. The product and service offerings depicted in this document are produced by Epicor Software Corporation. Results are not guaranteed, and each user’s experience will vary.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005167/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
